Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.7%. By the end of trading, Valeant Pharmaceuticals International fell 78 cents (-1.2%) to $66.24 on average volume. Throughout the day, 1.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in price between $66.09-$67.65 after having opened the day at $67.03 as compared to the previous trading day's close of $67.02. Other companies within the Drugs industry that declined today were: Oncolytics Biotech ( ONCY), down 16.5%, Aoxing Pharmaceutical Company ( AXN), down 14.6%, Oramed Pharmaceuticals ( ORMP), down 12.5%, and Bacterin International Holdings ( BONE), down 11.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $20.28 billion and is part of the health care sector. The company has a P/E ratio of 831.6, above the S&P 500 P/E ratio of 17.7. Shares are up 11.3% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Valeant Pharmaceuticals International a buy, one analyst rates it a sell, and four rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the positive front, Chelsea Therapeutics International ( CHTP), up 153.9%, Novogen ( NVGN), up 26%, Cornerstone Therapeutics ( CRTX), up 24.6%, and Cormedix ( CRMD), up 12.1%, were all gainers within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year